title: Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
abstract: BACKGROUND
  Psoralen plus ultraviolet A (PUVA) is the standard treatment for early stages of mycosis fungoides. There have been no adequate randomized controlled trials with sufficient power comparing this modality with other therapies.
  
  
  OBJECTIVE
  To assess disease response and to compare the response rates of patients treated with PUVA alone or PUVA and bexarotene.
  
  
  METHODS
  EORTC 21011 (NCT 00056056) was a randomized phase III study comparing combined bexarotene (Targretin(®) ) and PUVA vs. PUVA alone in patients with stage IB and IIA mycosis fungoides (MF). The primary endpoint was the overall response rate [complete clinical response (CCR) plus partial response (PR)].
  
  
  RESULTS
  The study was prematurely closed due to low accrual after 93 of 145 required patients (65%) were randomized. Of the 93 randomized patients, 87 started treatment, 41 received PUVA and 46 received PUVA + bexarotene. Total UVA doses received were 107 J cm(-2) (range 1·4-489·9) in the PUVA arm vs. 101·7 J cm(-2) (0·2-529·9) in the combination arm. The safety profile was acceptable with few grade 3-4 toxicities observed in either arm. More drop-outs due to toxicity were observed in the combination arm compared with the PUVA-alone arm. The best overall response (CCR + PR) rate was 71% for PUVA alone and 77% for the combination arm (P = 0·57). The median duration of response was 9·7 months for PUVA vs. 5·8 months for the combination arm (P = 0·33). CCR was seen in 25 patients of whom 10 received PUVA alone (CCR 22%) and 15 received combination therapy (CCR 31%) (P = 0·45). CCR was sustained in 25% of patients regardless of therapy. There was a trend towards fewer PUVA sessions needed to achieve CCR in the combination arm (median 22) compared with the PUVA arm (median 27·5) (P = 0·11). Similarly, a trend towards lower UVA dose required to achieve CCR in the combination arm (median 55·8 J cm(-2) ) compared with the PUVA arm alone (median 117·5 J cm(-2) ) (P = 0·5) was observed.
  
  
  CONCLUSIONS
  No significant difference in response rate or response duration was observed in this study. However, there was a trend towards fewer PUVA sessions and lower UVA dose required to achieve CCR in the combination arm (PUVA + bexarotene) but this did not achieve statistical significance due to insufficient power.
authors.affiliation: St John's Institute of Dermatology, King's College London, London, UK.
authors.forename: S
authors.initials: S
authors.lastname: Whittaker
authors.forename: P
authors.initials: P
authors.lastname: Ortiz
authors.forename: R
authors.initials: R
authors.lastname: Dummer
authors.forename: A
authors.initials: A
authors.lastname: Ranki
authors.forename: B
authors.initials: B
authors.lastname: Hasan
authors.forename: B
authors.initials: B
authors.lastname: Meulemans
authors.forename: S
authors.initials: S
authors.lastname: Gellrich
authors.forename: R
authors.initials: R
authors.lastname: Knobler
authors.forename: R
authors.initials: R
authors.lastname: Stadler
authors.forename: M
authors.initials: M
authors.lastname: Karrasch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077610:Bexarotene; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D057239:Early Termination of Clinical Trials; D006801:Humans; D007223:Infant; D008730:Methoxsalen / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D011701:PUVA Therapy / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D016588:Anticarcinogenic Agents; D017319:Photosensitizing Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene; D008730:Methoxsalen